Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM
The BCL-2 inhibitor lisaftoclax was well tolerated and produced encouraging responses in relapsed/refractory multiple myeloma when given in combination with Pd.
Related Articles
100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis
Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.
ctDNA and beyond to serve immunotherapy
Recent findings consolidate the role of liquid biopsy in the field, but prospective research is needed
How newer bispecifics, including teclistamab & talquetamab, may influence myeloma treatment
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the potential of bispecific antibodies in multiple myeloma, specifically…
MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis
Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.
Pacritinib and Momelotinib Display Positive Real-World Impact on Anemia and Transfusion Needs in Myelofibrosis
Pacritinib and momelotinib both demonstrated favorable real-world effects on anemia and transfusion requirements among patients with myelofibrosis.
Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
The OncFive: Top Oncology Articles for the Week of 12/18
Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.
Campbell Surveys Participants on Favorable-Risk Frontline Approach in RCC
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old patient with lung-metastatic renal cell carcinoma.
ICIs Result in Increased Rates of High-Grade irAEs for Older Patients With Breast Cancer
The risk of developing high-grade immune-related AEs was heightened among patients with breast cancer who were older and who had chronic kidney disease.
FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative…